Head to head
Fortrea Holdings vs Vertex Pharmaceuticals
Side-by-side on the measures that matter, with a plain-English read. Full detail: FTRE · VRTX
FTRE
Fortrea Holdings
18.55-7.94%
1-year price shape — +85% over the period
Quant Rating C · 96/100
vs
VRTX
Vertex Pharmaceuticals
515.02-1.08%
1-year price shape — +22% over the period
Quant Rating C · 68/100
1-year performance, rebased to 100
Vertex Pharmaceuticals edges it on the scoreable measures. Vertex Pharmaceuticals earns the most per share.
| FTRE | VRTX | |
|---|---|---|
| Snapshot | ||
| Sector | Biotechnology | Biotechnology |
| Last price | 18.55 | 515.02 |
| Change today | -7.94% | -1.08% |
| 1-year return | +84.8% | +22.0% |
| Market cap | $1.79B | $130.58B |
| 52-week range | 8.55 – 26.16 | 412.27 – 568.67 |
| Valuation | ||
| P/E (TTM) | -28.11 | 33.14 |
| P/E percentile, own 5-yr range | 14th | 99th |
| P/B | 3.36 | 6.25 |
| Dividend yield | 0.00% | 0.00% |
| Profitability & growth | ||
| EPS (TTM) | -10.81 | 15.32 |
| Net profit (TTM) | $-1.04B | $3.88B |
| Revenue (TTM) | $2.67B | $12.95B |
| Provider revenue period date | 2026-09-29 | 2026-09-29 |
| Revenue growth (YoY) | -1.4% | +11.8% |
| Gross margin | 20.0% | 85.5% |
| Operating margin | 1.7% | 33.1% |
| Net margin | -2.6% | 30.7% |
| Free cash flow (TTM) | $169.00M | $3.20B |
| Provider cash-flow period date | 2026-09-29 | 2026-09-29 |
| Ownership & sentiment | ||
| Institutional ownership | 110.3% | 96.8% |
| Insider activity (12mo) | 23 buy / 24 sell | 28 buy / 22 sell |
| Short interest (% of float) | 8.9% | 1.9% |
| Analyst consensus | 64% buy / 18% hold / 18% sell (11) | 95% buy / 5% hold (21) |
| Analyst price target | $25 (+35%) | $624 (+21%) |
| StockVane view | ||
| StockVane Quant Rating | C (96) | C (68) |
| Company | ||
| Employees | 14,300 | 6,400 |
| Founded | 2023 | 1989 |
▲ marks the more favourable stock(s) on measures with a clear direction (lower P/E, higher yield, higher Quant Rating, better 1-year return). Analyst consensus counts each covering institution once, at its most recent rating. Not a recommendation. Quant Rating method: Data & Methodology.